Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04857437 · ClinicalTrials.gov registry record · Phase 1

Study in Healthy Adults Evaluating PF-07202954

A Phase 1 study, sponsored by Pfizer.

Completed
Registry status
Phase 1
Development phase
12
Enrollment target

NCT04857437 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 12 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04857437, a Phase 1 study, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 1
Development phase
12 participants
Enrollment target

Study Summary

The study is planned as a 3 part design with investigator and participant blinded (sponsor-open), placebo controlled, randomized, dose escalation in Part 1 and Part 2; and a randomized, open label design, in Part 3 (if conducted).

Interventions

  • DRUG Placebo
  • DRUG PF-07202954 Repeat Dose
  • DRUG PF-07202954 Single Dose

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2021-05-13
Est. Completion 2021-09-17
Phase Phase 1

Sponsor

Pfizer

1,845 total trials

What the Registry Record Tells You About NCT04857437

The ClinicalTrials.gov registry entry for NCT04857437 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.

NCT04857437 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04857437 about?

NCT04857437 is a clinical study titled "Study in Healthy Adults Evaluating PF-07202954". The study is planned as a 3 part design with investigator and participant blinded (sponsor-open), placebo controlled, randomized, dose escalation in Part 1 and Part 2; and a randomized, open label design, in Part 3 (if conducted).

What is the current status of trial NCT04857437?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2021-05-13. Estimated completion is 2021-09-17.

What interventions are being tested in trial NCT04857437?

The interventions under investigation include: Placebo (DRUG), PF-07202954 Repeat Dose (DRUG), PF-07202954 Single Dose (DRUG).

Who is sponsoring clinical trial NCT04857437?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.